UCB Developed Brands
The computed 12-month bankruptcy probability of UCB Developed Brands is 0.8% (low). The 2025 annual accounts show equity of €867.82M and a net result of €827.12M. The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €867.82M |
| Net result | €827.12M |
| Staff (FTE) | 20.7 |
| Active | 1 yrs |
Exceptional profile, strong across almost every axis.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Fiscal year | 2025 |
|---|---|
| Revenue | €1.25B |
| EBITDA | €1.04B |
| Net profit | €827.12M |
| Cash flow | €878.11M |
| Staff costs | €4.04M |
| Income taxes | €162.04M |
| Dividends | - |
| Total assets | €1.07B |
| Equity | €867.82M |
| Debt | €198.40M |
| of which ≤ 1y | €198.16M |
| of which > 1y | - |
| Working capital | €868.74M |
| Employees (FTE) | 20.7 |
| 2025 | |
|---|---|
| Current ratio | 5.38 |
| Quick ratio | 5.38 |
| Working capital ratio | 81.1% |
| Solvency | 81.0% |
| Debt / equity | 0.23 |
| Long-term debt ratio | - |
| Interest coverage | 3893.88 |
| Gross margin | - |
| Net margin | 66.1% |
| ROA | 77.2% |
| ROE | 95.3% |
| EBITDA margin | 83.1% |
| Days sales outstanding | 171d |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €1.07B |
| Fixed assets | 21/28 | €4.17M |
| Intangible fixed assets | 21 | €4.17M |
| Current assets | 29/58 | €1.07B |
| Amounts receivable within one year | 40/41 | €1.02B |
| Cash & bank | 54/58 | €133 |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.07B |
| Equity | 10/15 | €867.82M |
| Contributions / capital | 10/11 | €75.73M |
| Accumulated profits (losses) | 14 | €792.09M |
| Provisions & deferred taxes | 16 | €4.85M |
| Amounts payable | 17/49 | €198.40M |
| Amounts payable within one year | 42/48 | €198.16M |
| Trade debts payable within one year | 44 | €115.21M |
| Income statement | ||
| Turnover | 70 | €1.25B |
| Operating result | 9901 | €988.80M |
| Financial income | 75 | €853k |
| Financial charges | 65 | €489k |
| Result before taxes | 9903 | €989.16M |
| Income taxes | 67/77 | €162.04M |
| Net result for the period | 9904 | €827.12M |
| Result to be appropriated | 9905 | €827.12M |
| NACE primary | 72101 |
| Legal form | Private limited company(610) |
| Incorporation | 17-12-2024 |
| Status | Active |
| Postal code | 1070 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25743G0274/00E002 | Wallonia | 18.8 ha | 1 · 5,615 m² | - |
| 21307F0123/00P000 | Brussels | 3.9 ha | 1 · 4,201 m² | 18.7 m · 4 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
02-01-2026 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2025-12-23",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB DEVELOPED BRANDS",
"legal_form": "SRL"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}02-10-2025 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB DEVELOPED BRANDS",
"legal_form": "SRL"
}
}11-06-2025 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": null,
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2025-06-11",
"filing_date": "2025-06-03",
"act_kind_objet": ""
},
"decision": {
"body": "enig_aandeelhouder_schriftelijk",
"act_date": "2025-05-26",
"unanimous": true
},
"conversion": null,
"detected_kind": "substantive_delegation",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "1017.533.562",
"name": "UCB Developed Brands",
"role": "contributor",
"address": "All\u00E9e de la Recherche 60 - 1070 Bruxelles (Anderlecht)",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e",
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": null,
"legal_articles": [
"2:8 \u00A74"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": null,
"real_estate_included": false,
"patrimony_description": null,
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB Developed Brands",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Philip Van Nevel",
"org_rep_person_name": null
},
"summary_narrative": "Cette communication de d\u00E9p\u00F4t informe que toutes les actions de la soci\u00E9t\u00E9 UCB Developed Brands sont r\u00E9unies en une seule main, identifiant ainsi l\u0027actionnaire unique. Une procuration sp\u00E9ciale est octroy\u00E9e \u00E0 plusieurs personnes et \u00E0 l\u0027avocat de Freshfields Bruckhaus Deringer LLP pour accomplir les formalit\u00E9s de publication des r\u00E9solutions des administrateurs.",
"co_filed_documents": [
"R\u00E9solutions \u00E9crites des administrateurs de la soci\u00E9t\u00E9 du 26 mai 2025"
],
"detected_real_type": "substantive_delegation",
"referenced_correction": null,
"should_reroute_to_category": null
}12-05-2025 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2025-05-01",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB DEVELOPED BRANDS",
"legal_form": "SRL"
},
"signature_regime": null,
"special_mandates": [
{
"quote": "\u00E0 Matthieu Derynck et tout autre notaire belge et tout employ\u00E9 de l\u2019\u00E9tude des notaires \u00AB Van Halteren Notaires \u00BB, agissant s\u00E9par\u00E9ment, en vue d\u2019\u00E9tablir le texte coordonn\u00E9 des statuts",
"holder_kbo": null,
"holder_name": "Matthieu Derynck",
"scope_categories": [
"publication",
"filing"
],
"with_substitution": false
},
{
"quote": "\u00E0 Matthieu Derynck et tout autre notaire belge et tout employ\u00E9 de l\u2019\u00E9tude des notaires \u00AB Van Halteren Notaires \u00BB, agissant s\u00E9par\u00E9ment, en vue d\u2019\u00E9tablir le texte coordonn\u00E9 des statuts",
"holder_kbo": null,
"holder_name": "Van Halteren Notaires",
"scope_categories": [
"publication",
"filing"
],
"with_substitution": false
}
],
"governance_change": {
"admin_delegated_added": []
}
}18-03-2025 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": "proposal",
"notary": {
"name": "Samuel Wynant",
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2025-03-18",
"filing_date": "2025-03-14",
"act_kind_objet": "DIVERS"
},
"decision": {
"body": null,
"act_date": "2025-03-14",
"unanimous": true
},
"conversion": null,
"detected_kind": "demerger_partial",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0543.573.053",
"name": "UCB Biopharma",
"role": "demerged",
"address": "All\u00E9e de la Recherche 60, 1070 Anderlecht",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "1017.533.562",
"name": "UCB Developed Brands",
"role": "recipient",
"address": "All\u00E9e de la Recherche 60, 1070 Anderlecht",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"12:8, 1\u00B0",
"12:4",
"12:59",
"12:67",
"12:69",
"12:62",
"12:13, 3\u00B0",
"12:60"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": "une action ordinaire d\u2019UCB Developed Brands",
"new_shares_issued_n": 32383629,
"real_estate_included": false,
"patrimony_description": "Les actifs et passifs relatifs au Portfolio Mature, comprenant principalement les m\u00E9dicaments Cimzia\u00AE, Keppra\u00AE et Briviact\u00AE, seront scind\u00E9s et apport\u00E9s \u00E0 UCB Developed Brands.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB Biopharma",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"_kbo_extracted_mismatch": "0543.573.053"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Samuel Wynant",
"org_rep_person_name": null
},
"summary_narrative": "Les conseils d\u2019administration d\u2019UCB Biopharma et UCB Developed Brands ont approuv\u00E9 un projet de scission partielle pour transf\u00E9rer les actifs et passifs du Portfolio Mature d\u2019UCB Biopharma \u00E0 UCB Developed Brands en \u00E9change de nouvelles actions ordinaires \u00E9mises par cette derni\u00E8re. L\u0027op\u00E9ration est pr\u00E9vue pour entrer en vigueur le 1er mai 2025.",
"co_filed_documents": [],
"detected_real_type": "demerger_proposal",
"referenced_correction": null,
"should_reroute_to_category": null
}19-12-2024 Incorporation of a new SRL
Technical details
{
"kind": "oprichting",
"seat": "All\u00E9e de la Recherche 60, 1070 Anderlecht",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": "0403.096.168",
"name": "UCB PHARMA"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "unique",
"partner_role": null,
"holder_org_kbo": "0403.096.168",
"holder_org_name": "UCB PHARMA",
"contribution_type": "cash",
"amount_paid_in_eur": 50000,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 1,
"amount_subscribed_eur": 50000,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 50000,
"subject_company": {
"kbo": "1017.533.562",
"name_full": "UCB Developed Brands",
"legal_form": "SRL"
},
"initial_directors": [],
"incorporation_date": "2024-12-13",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | UCB Developed Brands |